Streetbeat News

Revenues

BAND

Bandwidth Inc. projects a 16% increase in revenue and a 50% growth in profitability for the year 2024, indicating a positive outlook for the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:07 pm

BKSY

BlackSky projects its FY24 revenue to be between $102M and $118M, which is slightly below the consensus estimate of $118.71M. The company also anticipates an adjusted EBITDA ranging from $8M to $16M.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:06 pm

QRTEA

Qurate Retail (QRTEA) reported Q4 2023 adjusted earnings per share of $0.22 and sales of $3.14B, surpassing the $3.12B estimate. This represents a 10.86% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:05 pm

FLGT

Fulgent Genetics (FLGT) projects its 2024 core revenue to be around $280M, falling short of the consensus estimate of $294.25M. Additionally, it anticipates an adjusted EPS loss of approximately $(1.05), which is worse than the consensus forecast of $(0.95).

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:05 pm

VST

Vistra has reaffirmed its financial guidance for FY24, maintaining its expected ranges for Adjusted EBITDA ($3,700 - $4,100 million) and Adjusted Free Cash Flow before Growth (FCFbG) ($1,900 - $2,300 million).

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:03 pm

EDIT

Editas Medicine (NASDAQ:EDIT) reported Q4 earnings with a per-share loss of $(0.23), surpassing the $(0.54) estimate, marking a significant improvement from last year's $(0.88) loss. Quarterly sales reached $60.05M, greatly exceeding the $7.94M forecast and showing an 818.76% increase from the previous year's $6.54M. The company's cash and equivalents stand at $427.1M.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:02 pm

CAVA

Cava Group (NYSE:CAVA) has been evaluated by 4 analysts over the last three months, all giving somewhat bullish ratings. The average 12-month price target for CAVA is $58.00, up from $56.50, with a high of $65.00 and a low of $46.00. Analysts from Wedbush, Baird, and TD Cowen have raised their price targets, reflecting positive sentiment towards CAVA's financial performance, including a 26.06% revenue growth and a net margin of 3.89%. However, concerns are raised with a below-average ROE of 1.22%.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 12:00 pm

ACAD

13 analysts have recently updated their ratings on ACADIA Pharmaceuticals (NASDAQ:ACAD), showing a mix of bullish to bearish sentiments. The average 12-month price target is now $35.31, up from $32.00, with a range from $25.00 to $42.00. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their views on the company's market position and financial performance. ACADIA Pharmaceuticals, a biotech firm focusing on central nervous system disorders, has shown a notable revenue growth of 61.96% as of September 30, 2023, and has a strong market presence with a market capitalization above industry benchmarks.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 12:00 pm

RCM

R1 RCM (NASDAQ:RCM) has received mixed evaluations from 10 financial analysts over the past three months, with a current average 12-month price target of $15.5, down from $16.30. The company has shown positive revenue growth of 15.6% as of September 30, 2023, and has a net margin of 0.23%, indicating strong profitability. However, its ROA is below industry benchmarks. Analysts have made various adjustments to their ratings and price targets, reflecting their views on the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 12:00 pm

FOUR

Shift4 Payments (NYSE:FOUR) has been analyzed by 9 financial analysts, showing a mix of bullish to bearish sentiments. The average 12-month price target is $84.78, up 15.82% from the previous $73.20, with a range from $49.00 to $96.00. Analyst actions include maintaining, raising, and announcing ratings, with most analysts optimistic about the company's future. Shift4 Payments is noted for its integrated payment processing solutions, showing strong revenue growth and ROE but facing challenges in net margin and debt management.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 12:00 pm